6 results about "Recombinant interferon" patented technology

Disclosed are a recombinant interferon drug targeting a conserved HIV gp41 subunit membrane-proximal external region (MPER) and a use thereof. Specifically, disclosed is a targeted interferon fusion protein ZP-IC, comprising a 10E8 antibody or an antigen-binding fragment thereof, and an integrated interferon α, wherein the 10E8 antibody or the antigen-binding fragment thereof is linked to the integrated interferon α by means of a linker. In the present invention, the 10E8 antibody capable of identifying a highly conserved gp41 subunit MPER of an HIV envelope glycoprotein is used as a targeting tool for the integrated interferon. Therefore, a target exposed by a conformational change of a viral envelope protein during the infection of a cell can be accurately identified, viral infection is prevented, and a neutralizing effect is exerted; and in addition, a carried interferon molecule can more effectively bind to an interferon receptor on a cell around the HIV virus and achieve an antiviral role. Experiments have demonstrated that the ZP-IC has excellent antiviral activity and the capability of inhibiting an overwhelming majority of HIV strains across a broad spectrum.

The invention discloses a kit for detecting alpha-interferon and related application, and relates to the field of biology, the kit comprises a capture protein for capturing the alpha-interferon and a detection protein for detecting the alpha-interferon; the capture protein comprises receptor protein of alpha-interferon; the detection protein comprises an anti-alpha-interferon antibody; the kit is applied to IFN-alpha detection, can cover various subtypes of IFN-alpha, including natural interferon and recombinant interferon, has no cross reaction with INF-beta and INF-epsilon, is high in detection accuracy and good in repeatability, and can quickly and effectively detect the content of IFN-alpha in human serum, so that the overall level and the active state of IFN-alpha in vivo are reflected more accurately; the method is of great significance to understanding the human immune state, diagnosing and monitoring the development of diseases and evaluating the effectiveness of treatment.

The invention relates to canine recombinant interferon-alpha3 and application thereof, and relates to the technical field of biological products. The amino acid sequence of the canine recombinant interferon-alpha3 disclosed by the invention is as shown in SEQ ID NO. 2. The nucleotide sequence of the nucleic acid molecule for coding the canine recombinant interferon-alpha3 is as shown in SEQ ID NO. 1. According to the present invention, the secretory expression of the canine recombinant interferon-alpha3 in the pichia pastoris is achieved, the canine recombinant interferon-alpha3 with efficient antiviral activity is obtained, and the antiviral activity of the canine recombinant interferon-alpha3 is improved by optimizing the pichia pastoris expression system.

This invention discloses a kit for detecting α-interferon and related applications, relating to the biological field. The kit includes a capture protein for capturing α-interferon and a detection protein for detecting α-interferon; the capture protein includes an α-interferon receptor protein; the detection protein includes an antibody against α-interferon. This kit is applied to IFN-α detection, covering multiple IFN-α subtypes, including natural and recombinant interferon, and exhibits no cross-reactivity with INF-β and INF-ε. It has high detection accuracy and good repeatability, enabling rapid and effective detection of IFN-α levels in human serum, thereby more accurately reflecting the overall level and activity status of IFN-α in the body. This is of great significance for understanding human immune status, diagnosing and monitoring disease development, and evaluating the effectiveness of treatment.

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and / or preventing postoperative tumor recurrence and / or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and / or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

The invention discloses a cat omega interferon RNA vaccine and application thereof, and relates to the technical field of veterinary biological products. After the optimized cat omega interferon is used for immunizing an experimental animal, virus replication can be inhibited, so that the effect of protecting the body is achieved. Therefore, the nucleic acid molecule provided by the invention can be used for developing recombinant protein vaccines or preparing nucleic acid vaccines. Compared with the recombinant interferon protein on the market, the vaccine provided by the invention has the capability of enhancing the neutralizing antibody level of various vaccines, and can efficiently reduce the virus titer, interfere the combination of the virus and a host cell receptor and inhibit the replication of the virus, thereby playing a role in protecting the body and promoting the antiviral capability of the body.